Cover Image
Market Research Report

Global Myelofibrosis Therapeutics Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 773824
Published Content info 106 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Myelofibrosis Therapeutics Market 2018-2022
Published: December 21, 2018 Content info: 106 Pages
Description

About this market

Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio's analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.

Market Overview

Increasing number of companies entering the myelofibrosis segment

Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.

Limited market size as myelofibrosis is a rare disorder

The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.

For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.

Competitive Landscape

The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR23859

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

Market definition

  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT

  • Segmentation by type of treatment
  • Comparison by type of treatment
  • Drug therapy - Market size and forecast 2017-2022
  • Blood transfusion - Market size and forecast 2017-2022
  • HSCT - Market size and forecast 2017-2022
  • Androgen Therapy - Market size and forecast 2017-2022
  • Market opportunity by type of treatment

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • HSCT is the only curative option for myelofibrosis
  • High off-label prescription including hydroxyurea, Immunomodulators, and steroids

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for myelofibrosis 2017-2018
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Type of treatment - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by type of treatment
  • Exhibit 21: Drug therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: JAKAVI/JAKAFI sales from 2015-2017
  • Exhibit 23: Drug therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: *Blood transfusion - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Blood transfusion - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: HSCT - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 27: HSCT - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Androgen therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 29: Androgen Therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 30: Market opportunity by type of treatment
  • Exhibit 31: Customer landscape
  • Exhibit 32: Global - Market share by geography 2017-2022 (%)
  • Exhibit 33: Regional comparison
  • Exhibit 34: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 35: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 36: Top 3 countries in Americas
  • Exhibit 37: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 38: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top 3 countries in EMEA
  • Exhibit 40: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 41: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 42: Top 3 countries in APAC
  • Exhibit 43: Market opportunity
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bristol-Myers Squibb - Overview
  • Exhibit 49: Bristol-Myers Squibb - Business segments
  • Exhibit 50: Bristol-Myers Squibb - Organizational developments
  • Exhibit 51: Bristol-Myers Squibb - Geographic focus
  • Exhibit 52: Bristol-Myers Squibb - Key offerings
  • Exhibit 53: Bristol-Myers Squibb - Key customers
  • Exhibit 54: CELGENE - Overview
  • Exhibit 55: CELGENE - Business segments
  • Exhibit 56: CELGENE - Organizational developments
  • Exhibit 57: CELGENE - Geographic focus
  • Exhibit 58: CELGENE - Key offerings
  • Exhibit 59: CELGENE - Key customers
  • Exhibit 60: Incyte - Overview
  • Exhibit 61: Incyte - Business segments
  • Exhibit 62: Incyte - Organizational developments
  • Exhibit 63: Incyte - Geographic focus
  • Exhibit 64: Incyte - Key offerings
  • Exhibit 65: Incyte - Key customers
  • Exhibit 66: Novartis - Overview
  • Exhibit 67: Novartis - Business segments
  • Exhibit 68: Novartis - Organizational developments
  • Exhibit 69: Novartis - Geographic focus
  • Exhibit 70: Novartis - Segment focus
  • Exhibit 71: Novartis - Key offerings
  • Exhibit 72: Novartis - Key customers
Back to Top